Compare
Solid Biosciences Inc. vs DBV Technologies S.A. vs TScan Therapeutics, Inc. vs Century Therapeutics, Inc.
| Latest fiscal year | Solid Biosciences Inc. SLDB | DBV Technologies S.A. DBVT | TScan Therapeutics, Inc. TCRX | Century Therapeutics, Inc. IPSC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $5.64M | $10.32M | $109.16M |
| Revenue growth (YoY) | n/a | +35.8% | +266.7% | n/m |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/m | -15.8% |
| Net margin | n/a | n/m | n/m | -8.8% |
| Net income | -$174.32M | -$146.95M | -$129.77M | -$9.58M |
| EPS (Diluted) | -$1.99 | -$1.05 | -$1.00 | -$0.14 |
| Operating cash flow | -$156.29M | -$121.18M | -$135.32M | -$103.88M |
| Free cash flow | -$157.44M | -$121.71M | -$139.73M | -$104.72M |
| Cash & equivalents | $59.90M | $194.17M | $152.41M | $61.85M |
| Total assets | $232.54M | $233.72M | $228.79M | $223.70M |
| Total liabilities | $52.53M | $64.95M | $105.67M | $64.77M |
| Shareholders' equity | $180.01M | $168.77M | $123.12M | $158.94M |
| Return on year-end equity | -96.8% | -87.1% | -105.4% | -6.0% |
| Shares outstanding | 78.97M | n/a | n/a | 87.52M |
Revenue, most recent five fiscal years
| Fiscal year | Solid Biosciences Inc. | DBV Technologies S.A. | TScan Therapeutics, Inc. | Century Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $8.09M Ended 2022-12-31 | $5.64M Ended 2025-12-31 | $10.32M Ended 2025-12-31 | $109.16M Ended 2025-12-31 |
| 1 year earlier | $13.62M Ended 2021-12-31 | $4.15M Ended 2024-12-31 | $2.82M Ended 2024-12-31 | $6.59M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2020-12-31 | $15.73M Ended 2023-12-31 | $21.05M Ended 2023-12-31 | $2.23M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2019-12-31 | $4.84M Ended 2022-12-31 | $13.54M Ended 2022-12-31 | $5.20M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2018-12-31 | $5.71M Ended 2021-12-31 | $10.14M Ended 2021-12-31 | n/a |